查詢結果分析
相關文獻
- The Effect of Low-Dose Deferoxamine on Anemia in Iron-Overloaded Hemodialysis Patients
- Molecular Analysis and Prenatal Diagnosis of β-Thalassemia in Taiwanese: A Current Status Review
- 當前重型海洋性貧血患童的治療與護理趨勢
- 地中海貧血(海洋性貧血)可以治癒嗎﹖
- 吃血補血,對嗎?淺談缺鐵性貧血
- 地中海貧血可以治好嗎?
- 惡性貧血(Pernicious Anemia)
- 慢性腎衰竭相關貧血的臨床執業準則
- 慢性腎衰竭相關貧血的臨床執業準則
- 慢性腎衰竭病患的貧血治療
頁籤選單縮合
題 名 | The Effect of Low-Dose Deferoxamine on Anemia in Iron-Overloaded Hemodialysis Patients=低劑量Deferoxamine在鐵過量血液透析病患貧血的影響 |
---|---|
作 者 | 楊松昇; 林石化; 朱柏齡; 吳三江; 吳家兆; 蔡文生; 林裕峰; | 書刊名 | Journal of Medical Sciences |
卷 期 | 22:6 2002.12[民91.12] |
頁 次 | 頁283-288 |
分類號 | 418.23 |
關鍵詞 | 鐵過量; 貧血; Anemia; Deferoxamine; Hemodialysis; Iron overload; |
語 文 | 英文(English) |
英文摘要 | Background : Iron-overloaded anemia is frequently encountered in hemodialysis (HD) patients despite of high-dose of recombinant human erythropoietin (r-HuEPO) has widely used. Deferoxamine (DFO) had been shown to improve iron utilization. This study was to assess the effect of low-dose DFO on anemia in r-HuEPO-resistant, iron-overloaded HD patients. Methods: Twelve HD patients had r-HuEPO-resistant (>200U/kg/wk s.c) normocytic anemia and iron overload, defined as transferrin saturation index (TSI) >25%, and serum ferritin >800 µg/L. Patient received DFO (5 mg/kg) infused during the last hour of each dialysis session for 8 weeks (wk). Serum levels of aluminum before DFO (Al(subscript basal)) and 42-48 hours after the 1st dose of DFO (Al(subscript post-DFO) )treatment were checked. Hemoglobin (Hb), hematocrit (Hct), serum iron (SI), total iron-binding capacity (TIBC), serum ferritin, and TSI were measured weekly. DFO response was defined as Hb and/or Hct got 10% increment. Results: After 8 wks’ DFO therapy, 5 patients were responders (R) (Hb: 8.2±0.2→9.5±0.3 g/L, p<0.01) and 7 patients were non-responders (Non-R) (Hb: 8.3±0.3→8.1±0.2 g/L). Hb increased after 2 wks' of DFO treatment in R. Three of the R remained had stable Hb 2 months after DFO cessation. The percentage of patients with diabetes (80% vs 14%, p<0.05), levels of pre-DFO serum total Ca+² (10.9±0.5 vs 9.4±0.3 mg/dl, p<0.05) were higher in R than Non-R. The Alpost-DFO (50.8±1.7 vs 38.5±5.1µg/L, p>0.05) and the increment from Al(subscript basal) to Al(subscript post-DFO) (28.0±7.1 vs 16.0±1.7 µg/L, p>0.05) tend to be higher but did not reach statistical significant level. None of the patients had DFO-related adverse effects. Conclusions: A positive effect of low-dose DFO treatment was only observed in some patients (42%) especially in diabetic patients. A higher dose or longer treatment using low-dose of DFO might be needed in Non-R. |
本系統中英文摘要資訊取自各篇刊載內容。